Who
Kenneth Galbraith
Chair & CEO
Company insider
Files Form 4 as: Chair & CEO, Zymeworks; Chair, President & CEO, Zymeworks; Director, MacroGenics; Director, Celator Pharmaceuticals.
In numbers
- Trades disclosed
- 68
- Buys
- 1
- Sells
- 7
- Bought
- $750K
- Sold
- $7.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 3 Jun 2013
- Last trade
- 12 Jan 2026
- Last filed
- 12 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —64,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $690K30,424 at $22.67 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —64,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —216,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —216,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —64,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $690K30,424 at $22.67 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —47,668 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $569K22,657 at $25.10 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —66,666 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,668 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,666 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $795K31,686 at $25.10 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —47,668 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —66,666 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.